Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction

Luke Grundy, … , Inmaculada Silos-Santiago, Stuart M. Brierley

*JCI Insight.* 2018;3(19):e121841. [https://doi.org/10.1172/jci.insight.121841](https://doi.org/10.1172/jci.insight.121841).

**Graphical abstract**

![Graphical abstract showing the effects of chronic linaclotide treatment on colonic and bladder innervation and function.](https://jci.me/121841/pdf)
Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction

Luke Grundy,1,2 Andrea M. Harrington,1,2 Joel Castro,1,2 Sonia Garcia-Caraballo,1,2 Annemie Deiteren,1,2 Jessica Maddern,1,2 Grigori Y. Rychkov,2 Pei Ge,3 Stefanie Peters,4 Robert Feil,5 Paul Miller,3 Andre Ghetti,3 Gerhard Hannig,1 Caroline B. Kurtz,6 Inmaculada Silos-Santiago,6 and Stuart M. Brierley1,2

1Visceral Pain Research Group, Centre for Neuroscience, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia. 2Centre for Nutrition and Gastrointestinal Diseases, Discipline of Medicine, University of Adelaide, North Terrace, Adelaide, South Australia, Australia, and South Australian Health and Medical Research Institute (SAHMRI), North Terrace, Adelaide, South Australia, Australia. 3Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA. 4Interfakultäres Institut für Biochemie, University of Tübingen, Tübingen, Germany. 5AnaBios, San Diego, California, USA. 6Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA.

Introduction

Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder affecting approximately 11% of the global population (1). IBS places a significant financial burden on society and negatively affects the quality of life of those affected (1, 2). IBS is characterized by chronic abdominal pain or discomfort associated with altered bowel habits and is subclassified as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and alternating/mixed IBS (A/M-IBS) (1, 2). Abdominal pain is a key clinical feature of IBS and, paradoxically, is the most difficult symptom to treat (1, 2). Opioids are frequently used for pain management, yet their chronic use causes tolerance, dependence, and reduced analgesic efficacy, resulting in the current “opioid epidemic” (3). Importantly, chronic opioid use causes severe constipation, making opioid use in patients who already have constipation, such as the 33% of IBS patients who have IBS-C, problematic. Accordingly, opioids are not efficacious in treating visceral pain, and new analgesic treatments for visceral pain syndromes such as IBS are urgently required.

We have shown that linaclotide, an FDA-approved, synthetic, 14-amino acid peptide agonist of guanylate cyclase-C (GC-C), improves abdominal pain and bowel symptoms in IBS-C patients (4, 5). Linaclotide is minimally absorbed and acts locally within the gastrointestinal tract on GC-C expressed on the...
luminal side of intestinal epithelial cells (4, 6, 7). In preclinical models, this interaction elevates intracellular and extracellular levels of cyclic GMP (cGMP), inducing fluid secretion and accelerating intestinal transit (4, 6, 8). Preclinical models also show that a single dose of linaclotide can induce acute analgesia (4, 9). This effect is proposed to be mediated by the downstream effector of GC-C, cGMP, released basolaterally from colonic epithelial cells via cGMP efflux pumps, which inhibits colonic nociceptors by a mechanism that is currently unclear but being actively investigated (4).

Notably, the number of linaclotide-treated IBS-C patients reporting a reduction in abdominal pain actually increases over time (4). In phase III clinical trials, approximately 30% of IBS-C patients had a >30% reduction in abdominal pain compared with baseline after 1 week of linaclotide treatment. This reduction in abdominal pain increased to >50% of linaclotide-treated patients by week 3 and >60% of linaclotide-treated patients by week 7 and was sustained at approximately 70% of linaclotide-treated patients for the remainder of the 26 weeks of treatment (4). However, the mechanisms underlying the enhanced analgesic effects following long-term linaclotide treatment remain unclear. Although the pathophysiology of IBS is not completely understood, hallmarks of IBS include allodynia and hyperalgesia to mechanical events within the intestine in the absence of overt pathology to the intestinal mucosa, suggesting neuroplasticity of colonic afferent pathways in the development and maintenance of chronic abdominal pain in IBS (1, 2, 10). Accordingly, we hypothesized that chronic linaclotide treatment and its downstream effector, intestinal epithelial cell–derived cGMP, may be responsible for persistent inhibition of colonic nociceptors, a reduction in peripheral afferent drive to the spinal cord, and, ultimately, reversal of the neuroplasticity underlying chronic abdominal pain.

In addition to chronic abdominal pain, IBS patients also suffer from extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS) (1, 11, 12). Of particular interest is the observation that bladder dysfunction is significantly more common among IBS patients than in healthy control subjects (1, 13–17). Correspondingly, IBS patients are more likely to report OAB symptoms, including nocturia, urgency, and urge incontinence (11, 13). These reports are intriguing, as the colon and bladder are both innervated by spinal afferents, which have peripheral endings within their host tissue, axons that travel via the splanchnic and pelvic nerves, cell bodies located within the thoracolumbar (TL) and lumbosacral (LS) dorsal root ganglia (DRG), and central projections that synapse into the dorsal horn of the TL and LS spinal cord (11). Subconscious coordination of sensory signals from the colon and bladder via these spinal pathways is essential for synchronized defecatory and micturition responses (11). Therefore, disruption of these intimate neural processes could result in comorbid conditions, such as IBS and OAB/IC-PBS (11). Animal models have shown that active colitis causes transient bladder overactivity and bladder afferent dysfunction (11, 14–17). However, the long-term effects of colitis on bladder function have not been correlated to chronic neuroplasticity of bladder afferent pathways. Furthermore, once established, it remains unclear if bladder dysfunction can be normalized with the use of therapeutic treatments. We hypothesized that colitis-induced neuroplasticity of colonic afferent pathways subsequently causes chronic hypersensitivity of afferent pathways innervating the bladder. We also hypothesized that chronic linaclotide administration to reduce peripheral sensory drive from the colon may therefore subsequently reverse bladder afferent hypersensitivity and restore normal bladder function.

Here, we demonstrate that colitis induces neuroplasticity in sensory pathways innervating the colon and then subsequently the bladder, resulting in concurrent chronic abdominal pain and bladder dysfunction in postinflammatory states in mice. Chronic linaclotide treatment reverses this neuroplasticity via a cGMP-dependent extracellular mechanism, alleviating abdominal pain and normalizing bladder function. These findings suggest that improving abdominal pain with linaclotide treatment, which is localized to and acts via GC-C within the gastrointestinal tract, may improve urological symptoms through inhibition of sensory pathways common to the colon and bladder.

**Results**

*Colitis induces chronic allodynia and hyperalgesia, which is reversed by chronic daily linaclotide treatment.* In order to determine if chronic linaclotide treatment (3 μg/kg by 100 μl oral gavage, ref. 9, once daily for 2 weeks) reduces chronic abdominal pain, we used an IBS mouse model of chronic visceral hypersensitivity (CVH). These mice were administered intracolonic trinitrobenzenesulfonic acid (TNBS) and developed colitis, as indicated by macroscopic damage, crypt segmentation, and edema to the colonic epithelium, in addition to significant increases in myeloperoxidase (MPO) activity (Supplemental Figure 1; supplemental material...
Colitis induces chronic hypersensitivity of colonic nociceptors, which is reversed by chronic daily linaclotide treatment. To determine if the linaclotide-induced reversal of allodynia and hyperalgesia in CVH states is due to long-term inhibition of peripheral sensory drive from the colon we performed ex vivo recordings of colonic nociceptors from mice administered either chronic linaclotide or vehicle. Colonic nociceptors from CVH mice displayed increased responsiveness to mechanical stimuli (4, 18-21). We found that control mice administered daily linaclotide displayed modest reductions in colonic afferent responses to mechanical stimuli relative to those of vehicle-treated control mice (Figure 1, E and F). In contrast, colonic nociceptors from CVH mice administered daily linaclotide for 2 weeks showed pronounced decreases in mechanical responsiveness (Figure 1, G and H) and normalized activation thresholds (Supplemental Figure 3) relative to those of vehicle-treated CVH mice. These findings suggest that chronic linaclotide treatment reverses the chronic mechanical hypersensitivity of colonic nociceptors normally observed in CVH states.

Colitis induces neuroplasticity within the dorsal horn of the spinal cord, which is reversed by chronic daily linaclotide treatment. We next assessed if the linaclotide-induced suppression in peripheral drive from the colon resulted in corresponding changes in nociceptive signaling within the dorsal horn of the spinal cord. To do this, we identified activated dorsal horn neurons in response to noxious (80 mmHg) CRD by phosphorylated MAP kinase ERK 1/2 immunoreactivity (pERK-IR). CVH mice treated with vehicle displayed significantly more activated dorsal horn neurons in response to noxious CRD compared with vehicle-treated CVH mice (Figure 2A). In control mice, daily linaclotide treatment did not alter the number of activated dorsal horn neurons after noxious CRD compared with vehicle-treated CVH mice (Figure 2A). In contrast, daily linaclotide treatment in CVH mice resulted in significantly fewer pERK-IR dorsal horn neurons after noxious CRD compared with vehicle-treated CVH mice (Figure 2A and C). This decrease was particularly apparent within lamina I, II, and V of the dorsal horn, with the number of activated neurons similar to that in control conditions (Figure 2). In order to determine if different populations of pERK-IR neurons were activated in CVH states, we colabeled for calbindin (excitatory neurons, ref. 22) or GABA (inhibitory interneurons, ref. 22; Supplemental Figure 4). While the number of pERK-IR neurons expressing calbindin did not change between conditions and treatments (Supplemental Figure 4, A and B), we observed a significant increase in the percentage of pERK-IR dorsal horn neurons expressing GABA (Supplemental Figure 4, C and D). This effect was partially reversed in CVH mice treated with linaclotide.

We have previously shown that CVH mice display sprouting within the spinal cord of the central terminals of colon-innervating afferents, particularly within lamina I but also deeper laminae (23). We therefore sought to determine if the linaclotide-induced decrease in peripheral sensory drive from the colon, plus the reduced activation of dorsal horn neurons in response to noxious CRD, would alter sprouting of colonic afferent central terminals in CVH states. We found that, relative to control animals, CVH vehicle-treated mice displayed an increased optical density (Figure 3A) and area covered by colonic afferent central terminals in the dorsal horn (laminae I and II) (Figure 3B), as identified by fluorescent retrograde labeling of colon-innervating neurons using CTB-555 (Figure 3C and Supplemental Figure 5). CVH mice treated daily with linaclotide showed a reduced density and distribution of colonic afferent central terminals, suggesting sprouting of these terminals within the spinal cord was not as extensive as that normally observed in CVH.
mice (Figure 3 and Supplemental Figure 5). Collectively, these findings suggest that daily linaclotide treatment reverses CVH-associated neuroplasticity in colonic afferent pathways.

Exogenous cGMP inhibits colon-innervating DRG neurons via a membrane receptor target that is accessed extracellularly. Previous studies suggest that the GC-C agonist linaclotide does not directly inhibit nociceptors, rather the downstream effector of GC-C, cGMP released basolaterally from colonic epithelial cells, inhibits colonic nociceptors (4). However, this mechanism and the manner in which cGMP exerts these inhibitory actions remain to be fully elucidated. Using whole-cell patch-clamp electrophysiology of colon-innervating DRG neurons, we confirmed that linaclotide does not affect the excitability of these neurons (Figure 4, A and B). Colon-innervating DRG neurons from CVH mice displayed pronounced neuronal hyperexcitability relative to that of control counterparts (Figure 4C). In contrast to linaclotide, exogenous application of cGMP inhibited a large population of colon-innervating DRG neurons, particularly in CVH states (Figure 4, D–F). In CVH DRG neurons, cGMP caused a dose-dependent inhibition of neuronal excitability, significantly increasing the amount of injected current required to fire an action potential (Figure 4, F and G). Importantly, cGMP was still able to inhibit colonic nociceptors from mice lacking GC-C (gucy2c−/−; Supplemental Figure 6).

Having confirmed that cGMP, rather than linaclotide, inhibits colonic nociceptors, the question remained as to the underlying mechanism. Although active mechanisms for transport of cGMP out of cells have been described, passive diffusion of cGMP across cell membrane is poor, and cGMP is not actively transported back into cells (24). We therefore hypothesized that the effects of cGMP on colonic nociceptors are via a membrane target accessible extracellularly. To investigate this, we utilized fluorescence resonance energy transfer–based
(FRET-based) analysis of genetically encoded fluorescent biosensors for cGMP. DRG neurons were isolated from R26-CAG-mcGi500(L1) mouse embryos, which express the membrane-targeted version of cGi500, a cGMP indicator with an EC50 of 500 nmol/l that displays fast binding kinetics and exquisite selectivity for cGMP (25–27). Application of C-type natriuretic peptide (CNP; used as a positive control, as it results in the intracellular production of cGMP) to R26-CAG-mcGi500 DRG neurons increased the CFP/YFP emission ratio in the cell soma (Figure 4, H, J, and L) and growth cones (Figure 4, I, K, and M), which is a measure of the intracellular cGMP concentration. In contrast, uroguanylin (an endogenous GC-C agonist) did not increase intracellular cGMP concentrations in either DRG soma (Figure 4, J and L) or growth cones (Figure 4, K and M), confirming a lack of functional GC-C expression by DRG neurons. Adding increasing concentrations of exogenous extracellularly applied cGMP did not change FRET ratio signals in either DRG soma (Figure 4, J and L) or growth cones (Figure 4, K and M), suggesting that cGMP is unable to cross neuronal membranes. However, deliberate permeabilization of the membrane with β-escin treatment, followed by exogenous extracellular cGMP, caused increased FRET signal ratios in both DRG soma (Figure 4, J and L) and growth cones (Figure 4, K and M), indicating that cGMP had accessed the intracellular space. Overall, these findings confirm that cGMP inhibits colonic nociceptors via a membrane target that is accessed extracellularly.

Human DRG neurons are also inhibited by exogenous cGMP. To further investigate the translatability of our findings, we tested the ability of exogenously applied cGMP to inhibit human DRG neurons from organ donors. Using whole-cell patch-clamp electrophysiology, we found that application of exogenous cGMP caused a dose-dependent decrease in the number of action potentials fired by human DRG neurons (Figure 5, A and B). In order to simulate a pathological state, we incubated a subset of the DRG neuronal cultures with an inflammatory soup (histamine: 10 M, PGE-II: 10 μM, serotonin: 10 μM, bradykinin: 10 μM) for 2 hours.
RESEARCH ARTICLE

Human DRG neurons from these cultures displayed pronounced hyperexcitability (Figure 5C), with application of exogenous cGMP causing a dose-dependent decrease in the number of action potentials fired (Figure 5, D and E). Overall, more human DRG neurons from the inflammatory soup cultures were inhibited by cGMP compared with human DRG neurons from the normal cultures (Figure 5F).

Mice with colitis-induced CVH display altered bladder-voiding patterns, an effect that is reversed by chronic daily linaclotide treatment. We hypothesized that mice with CVH following spontaneous recovery from TNBS-induced colitis also exhibit altered bladder function, indicating the development of an OAB/IC-PBS phenotype. To investigate this, we examined mouse bladder-voiding patterns before and at 7, 14, 21, and 28 days following intracolonic TNBS treatment (Figure 6). Filter paper samples from the cages of control mice showed a distinctly organized pattern of voiding throughout the time course of the experiment, from day 1 through day 28 (Figure 6, A–E). In contrast, CVH mice began to develop a disrupted, scattered voiding pattern by day 14 after intracolonic TNBS, which was maintained and exacerbated by day 28 (Figure 6, B–J).
Figure 4. Exogenous cGMP inhibits colon-innervating DRG neurons via a membrane target accessed from an extracellular site. (A) Whole-cell current-clamp recordings of retrogradely traced colon-innervating DRG neurons (n = 15). Bath application of linaclotide (1,000 nM) did not affect rheobase (amount of current required to fire an action potential). (B) Representative recordings in response to 500-millisecond current injection at rheobase (top) and 2× rheobase (bottom). Recordings were from the same neuron before and after linaclotide. (C) Colon-innervating DRG neurons from CVH mice (n = 36) display a reduced rheobase compared with controls (n = 30), indicating neuronal hyperexcitability (**P < 0.0001). (D) Percentage of colon-innervating DRG neurons from control and CVH mice inhibited by exogenous cGMP (0.1–10 μM). (E) Exogenous cGMP increases the rheobase of colon-innervating DRG neurons from control mice (n = 7) at 0.1 μM cGMP (**P < 0.05) and 1 μM cGMP (*P < 0.05) and (F) CVH mice (n = 9) at 1 μM (**P < 0.01) and 10 μM cGMP (**P < 0.001). (G) Recordings from a CVH colon-innervating DRG neuron to 500-millisecond current injections, showing rheobase at baseline and in the presence of 0.1–10 μM cGMP. (H) A dissociated E12.5 DRG neuron and (I) growth cones isolated from R26-CAG-mcGi500 mice, expressing the intracellular membrane-targeted mcGi500 (YFP fluorescence). In both examples, the red circle represents the region of interest (ROI) that was chosen for the measurement shown in J and K. Scale bars: 10 μm. Fluorescence resonance energy transfer (FRET)/cGMP measurements performed with embryonic (J) DRG neurons and (K) growth cones. An increase in the CFP/YFP emission ratio, R = F480/F535, indicates increased intracellular cGMP concentrations. FRET-based cGMP imaging was performed with drug stimulations (gray bars) in the following order: C-type natriuretic peptide (CNP, 0.1 μM), uroguanylin (UG; 1 μM), and 0.1, 10, and 100 μM cGMP. CFP (cyan) and YFP (yellow) emissions were recorded and the ratio (black) built, which corresponds to the intracellular cGMP concentration. After deliberate cell permeabilization with β-escin, cells were perfused with 1 μM cGMP (positive control). Group quantification of cGMP signals, showing extracellular cGMP does not enter the (L) somata of intact dissociated DRG neurons nor (M) their growth cones (**P < 0.0001; CNP vs. uroguanylin and cGMP (0.1–100 μM); μP < 0.01; cGMP permeabilization vs. uroguanylin and cGMP (0.1–100 μM). Data represent mean ± SEM. P values are based on paired t tests (A), unpaired t tests (C), or 1-way ANOVA with Tukey’s multiple comparison tests (E, F, L, and M).

At day 28, these changes were characterized by an increase in the number of small- and medium-sized urine spots (Figure 6, I and J) as well as an altered distribution throughout the cage, indicative of the OAB/IC-PBS symptoms of urgency and frequency. In CVH mice due to receive either vehicle or linaclotide treatment, we saw a similar pattern of voiding dysfunction at day 14 (Figure 6, C, D, G, and H). However, following initiation of chronic oral linaclotide administration (started on day 14 after intracolonic TNBS), CVH-induced changes in voiding patterns were attenuated, normalizing at day 28 both the distribution and the number of small- and medium-sized urine spots relative to vehicle-treated CVH mice (Figure 6, C–J). Notably, colitis did not induce local inflammation or changes in bladder histology at any time point tested following TNBS-induced colitis (Supplemental Figure 1), indicating that the changes we see in bladder-voiding patterns are not a direct result of local bladder inflammation.

CVH mice show enhanced bladder afferent responses to distension, which are reversed by chronic daily linaclotide treatment. To understand the mechanisms underlying the changes in bladder-voiding parameters observed in CVH mice, we next sought to examine bladder afferent responses to bladder distension. Multiunit ex vivo pelvic afferent recordings from control mice showed that, as pressure within the bladder increased, there was a corresponding increase in action potential discharge (Figure 7, A and B). However, bladder afferents from CVH mice displayed a significantly enhanced response to distension compared with control mice, particularly at 10–30 mmHg of bladder distension, pressures that are likely to trigger bladder voiding in states of OAB/IC-PBS (Figure 7, A and B). This suggests that the aberrant bladder-voiding patterns we observed in the current study could be mediated by changes in bladder afferent mechanosensitivity. Furthermore, by examining the pressure-volume relationship in the bladder during distension, we identified that there was no difference in muscle compliance (Supplemental Figure 7A) or contractility (Supplemental Figure 8A) between control and CVH mice. This suggests that the significant changes in bladder afferent mechanosensitivity in CVH mice are mediated at the level of the primary afferent, rather than secondary to changes in the ability of the bladder to accommodate an increase in volume. As we demonstrated that daily linaclotide is able to normalize bladder-voiding patterns and reduce colonic afferent sensitivity, we hypothesized that linaclotide may also be able to attenuate colitis-induced bladder hypersensitivity. Here, we show that CVH mice receiving daily linaclotide treatment had significantly reduced bladder afferent sensitivity to distension (0–30 mmHg) compared with vehicle-treated CVH mice (Figure 7, C and D). However, chronic linaclotide administration had no effect on bladder muscle compliance (Supplemental Figure 7B) or bladder muscle contractility (Supplemental Figure 8B), demonstrating that linaclotide’s effect on reducing bladder afferent mechanosensitivity is independent of altered muscle compliance or contractility.

Daily linaclotide treatment prevents colitis-induced increases in bladder afferent chemosensitivity. To further investigate the effects of the CVH state on bladder afferent function, we examined the effect of purinergic (P2X3), muscarinic, and transient receptor potential vanilloid 1 (TRPV1) receptor agonists on bladder afferent firing in control and CVH mice. Application of the individual agonists αβ Me-ATP, carbachol, or capsaicin, respectively, caused significant bladder afferent activity from control mice (Figure 7, E–G). However, afferent responses to these agonists were all significantly enhanced in bladder preparations from CVH mice (Figure 7, E–G). In contrast, CVH mice treated daily with linaclotide showed significantly reduced bladder
afferent responses to αβMe-ATP, carbachol, and capsaicin compared with CVH vehicle-treated mice (Figure 7, H–J), normalizing afferent responses to these agonists.

Chronic daily linaclotide reduces the excitability of bladder-innervating DRG neurons from CVH mice. In this study, we have shown that CVH mice display enhanced mechanical and chemical sensitivity of the peripheral sensory

Figure 5. Exogenous cGMP inhibits human DRG neurons. (A) Whole-cell current-clamp recordings from a human DRG neuron, showing action potential firing in response to increasing current injections (800–1,200 pA, 500-ms duration). Increasing concentrations of exogenous cGMP (0.1 μM, 1 μM, and 10 μM) caused dose-dependent decreases in action potential firing. (B) Group data showing exogenous cGMP inhibits firing in affected neurons (*P < 0.05). (C) Human DRG neurons incubated for 2 hours prior to patching with an inflammatory soup displayed increased neuronal excitability, indicated by reduced rheobase (**P < 0.01) compared with neurons in normal media. (D) Human DRG neurons incubated with inflammatory soup displayed reduced numbers of action potentials at 2× rheobase in the presence of cGMP (10 μM, *P < 0.05). (E) Whole-cell current-clamp recordings from a human DRG neuron incubated in inflammatory soup at baseline and in the presence of exogenous cGMP (0.1–10 μM). (F) More human DRG neurons incubated with inflammatory soup were inhibited by exogenous cGMP (10 μM). Data represent mean ± SEM. *P values are based on paired (B and D) or unpaired (C) t tests.
Figure 6. CVH mice display abnormal bladder voiding that is reversed by chronic oral administration of linaclotide. Filter paper images from individual mice followed for the duration of the 28-day study show (A) control mice (N = 9) have predictable voiding patterns throughout, while (B) CVH mice (N = 11) and (C) CVH mice receiving vehicle treatment (N = 10) develop altered voiding patterns from day 14 after intracolonic TNBS. (D) By contrast CVH mice chronically administered linaclotide (N = 10) show normalized bladder-voiding patterns at 28 day. Scale bars: 10 cm. (E) The number of small-, medium-,
and large-sized urine spots produced by control mice is similar for each time point throughout the 28-day study. (F) CVH mice display increased numbers of medium-sized urine spots at 28 days after intracolonic TNBS administration compared with baseline (day 1; prior to TNBS, **P < 0.01) or 7 days after TNBS (*P < 0.05, **P < 0.01). (G) CVH mice receiving vehicle treatment from 14–28 days after TNBS display increased numbers of medium-sized spots at day 21 (**P < 0.01) and day 28 after intracolonic TNBS (**P < 0.001). (H) CVH mice display more medium-sized urine spots at day 14 after TNBS (*P < 0.05), but, following chronic administration of linaclotide (from 14–28 days after intracolonic TNBS), the number of medium-sized urine spots is normalized. (I and J) Quantitative data at day 28 for all treatment groups showing a significant increase in (I) small- and (J) medium-sized spots in CVH (*P < 0.05, **P < 0.01) and CVH vehicle-treated (**P < 0.01) mice compared with control mice. Data represent mean ± SEM. P values are based on 1-way ANOVA followed by Bonferroni post hoc tests (E–J).

endings innervating the bladder and that these effects are independent of altered smooth muscle properties or local inflammation. To determine if this hypersensitivity occurs directly at the neuronal level, we used whole-cell patch-clamp electrophysiology to measure neuronal excitability of bladder-innervating DRG neurons. Retrogradely traced bladder-innervating TL and LS DRG neurons from CVH mice displayed pronounced hyperexcitability compared with those from control mice (Figure 8, A–C, and Supplemental Figure 9). Daily linaclotide treatment of CVH mice prevented CVH-induced hyperexcitability of bladder-innervating DRG neurons relative to vehicle-treated CVH mice (Figure 8, A–C, and Supplemental Figure 9). Overall, these findings indicate that colitis-induced sensitization of colonic afferents is able to sensitize the cell bodies of bladder afferents and that chronic administration of linaclotide can prevent bladder afferent hypersensitivity in CVH states.

The effects of linaclotide are not mediated via direct actions within the bladder. Although linaclotide has a very low oral bioavailability and its receptor, GC-C, has been shown to be almost exclusively expressed in the mucosa of the gastrointestinal tract (4), we wanted to confirm that the effects seen in this study were not mediated by direct actions of linaclotide upon the bladder. Using in situ hybridization, we confirmed our previous findings and showed that GC-C is highly expressed in colonic epithelial cells (Figure 8D). In contrast to the colon, expression of GC-C was not evident within the bladder (Figure 8D). To further confirm our findings, we performed qPCR analysis of mRNA isolated from either primary colonic epithelial cells or bladder urothelial cells. These studies revealed that the colonic mucosa contained abundant GC-C mRNA expression, whereas GC-C mRNA expression was absent from the bladder mucosa (Figure 8E). In contrast, TRPV4, known to be expressed in bladder urothelial cells (28), was abundantly expressed in bladder urothelium (Figure 8E). To functionally confirm a lack of action of linaclotide within the bladder, we used ex vivo bladder afferent recordings and infused linaclotide intravesically into the bladder during ramp distension (Figure 8, F and G). Intravesical linaclotide had no effect on bladder mechanosensitivity to bladder distension in either control or CVH mice (Figure 8, F and G). These findings support our hypothesis that the inhibitory effects of linaclotide treatment are not via a direct action within the bladder.

Crosstalk of colon and bladder afferents within the DRG and spinal cord. To investigate how bladder afferents become hypersensitive in CVH states and why CVH mice display bladder dysfunction, we performed concurrent retrograde tracing from the colon and bladder. This allowed us to determine if these organs are innervated by a substantial population of DRG neurons that have dichotomizing axons that project to both the colon and the bladder. We found that the vast majority (85%) of retrogradely traced DRG neurons in both control and CVH states contain only the tracer injected into the colon or the tracer injected into the bladder, with a small population of dual-labeled (15%) DRG neurons identified (Figure 9, A–F). A direct comparison of the number of traced colon-only, bladder-only, or dual-traced neurons per ganglia showed no significant alterations in the populations between control and CVH states in either TL or LS DRG (Figure 9, C and D). Furthermore, the percentage of colon-innervating neurons that also innervated the bladder (dual traced) did not alter between healthy and CVH mice (Figure 9, E and F). However, within the DRG it is evident that individual bladder- or colon- or dual-innervating neurons are located within close proximity to one another (Figure 9, A and B), allowing potential “crosstalk” between these organs. In separate tracing studies, we investigated the central terminals of colon-innervating and bladder-innervating afferents by visualizing retrograde tracing from each organ. These data show that the colon-only and bladder-only central terminals lie in very close proximity to one another within the dorsal horn of the spinal cord, in particular within laminae I, the lateral spinal nucleus, and the lumbar dorsal column (Figure 9, G–J). This close proximity provides potential opportunities for these central terminals to communicate with one another, allowing crosstalk between these organs onto shared spinal cord circuits. These findings may well explain why IBS patients have comorbidities, including abdominal pain and OAB/IC-PBS.
Discussion

IBS patients represent approximately 11% of the global population and suffer from chronic abdominal pain and altered gastrointestinal motility. The underlying pathogenesis of IBS is complex; however, there is a strong correlation between a prior exposure of the patient to gut infection and symptom occurrence (1, 2). Such bouts of acute gastroenteritis can trigger IBS symptoms in patients that persist for at least 8 years after the initial infection (29). IBS patients report visceral hypersensitivity but do not present with concurrent signs of gastrointestinal inflammation (1, 2, 10). It is therefore suggested that patients develop neuroplasticity of visceral sensory pathways, which drives chronic abdominal pain in the absence of pathology in the postinflammatory state (1, 10). Here, we demonstrate that, following resolution of colitis, in the postinflam- 

Figure 7. CVH mice display abnormal bladder afferent responses to mechanical and chemical stimuli that are reversed by chronic oral administration of linaclotide. (A) Ex vivo bladder afferent firing in response to ramp distension is increased in CVH (N = 11) compared with control (N = 10) mice (** ** P < 0.0001). (B) Ex vivo bladder multiunit recording from control or CVH mice showing action potential firing during bladder distension with intravesical saline. (C) CVH mice chronically administered linaclotide (N = 7) show reduced bladder afferent responses to distension compared with vehicle-treated CVH mice (N = 11; ***P < 0.001). (D) Ex vivo bladder multiunit recording from CVH mice treated with vehicle or daily linaclotide showing action potential firing during bladder distension with intravesical saline. (E-G) Bladder afferent responses to bath application of (E) αβMe-ATP (30 μM, ***P < 0.001), (F) carbachol (1 μM; *P < 0.05), and (G) capsaicin (10 μM, ***P < 0.001) are all enhanced in CVH (N = 5–7 mice/group) compared with control (N = 6 mice/group). (H-J) Bladder afferent responses to bath application of (H) αβMe-ATP (** ** P < 0.001), (I) carbachol (** ** P < 0.001), and (J) capsaicin (** ** P < 0.001) are all attenuated in CVH mice chronically administered linaclotide (N = 5–7 mice per group) compared with vehicle-treated CVH mice (N = 7 mice per group). Data represent mean ± SEM. P values above are based on 2-way ANOVA (A, C, and E–J), with subsequent Bonferroni post hoc test significance at individual data points indicated on E–J.
Figure 8. Chronic oral administration of linaclotide reverses CVH-induced bladder DRG neuronal hyperexcitability. (A) Whole-cell current-clamp recordings of retrogradely traced lumbosacral (LS) bladder-innervating DRG neurons, showing reduced rheobase of neurons from CVH (n = 18, **P < 0.01) and vehicle-treated CVH (n = 26, *P < 0.05) versus control (n = 20) mice. Bladder-innervating DRG neurons from mice chronically administered linaclotide (n = 27) showed normalized rheobase, which are significantly different compared to CVH neurons (*P < 0.05). (B) Action potential firing at 2× rheobase is increased in vehicle-treated CVH mice (*P < 0.05), while CVH mice receiving chronic linaclotide show normalized firing at 2× rheobase (*P < 0.05). (C) Whole-cell current-clamp traces at rheobase and 2× rheobase in bladder-innervating neurons from control, CVH, vehicle-treated CVH, and linaclotide-treated CVH mice. (D) Sections of colon and bladder at increasing magnifications showing in situ hybridization. GC-C is observed in...
colonic mucosa of GC-C (gucy2c<sup>+/+</sup>) wild-type, but not gucy2c-null (gucy2c<sup>−/−</sup>) mutant mice. GC-C expression is absent in bladder samples from both gucy2c<sup>+/+</sup> and gucy2c<sup>−/−</sup> mice. Results were repeated in N = 3 mice/group. Scale bars: 200 μm (top); 50 μm (middle); 25 μm (bottom). (E) Quantitative RT-PCR confirming expression of gucy2c in primary colonic epithelium and absence in primary bladder urothelium. In comparison, trpv4 is highly expressed in bladder urothelium (N = 4–6 mice/group). (F) Ex vivo bladder afferent mechanosensitivity to ramp distension is increased in CVH (N = 7) compared with control (N = 6) mice. Bladder afferent responses from control or CVH mice are unaltered following ex vivo intravesical infusion of linaclotide (1,000 nM), showing linaclotide does not directly inhibit bladder afferents. (G) Action potential firing and intravesical pressure from control compared with control (N = 4–6 mice/group). (N expressed in bladder urothelium (trpv4 is highly expressed). Results were repeated in N = 3 mice/group. Scale bars: 200 μm (middle); 25 μm (top); 50 μm (bottom). (μ = 7)

with the cell bodies of these afferents showing pronounced hyperexcitability. This increased nociceptive signal leads to increased activation of dorsal horn neurons within the spinal cord in response to noxious CRD. Notably, the neurochemistry of these activated dorsal horn neurons changes, with the recruitment of additional neuronal populations not seen in the healthy state. This may be a potential consequence of the increased density of the colonic afferent central terminals within dorsal horn lamina I and II. Correspondingly, CVH mice exhibited allodynia and hyperalgesia in response to CRD, indicative of chronic abdominal pain (Figure 9K). As this neuropathy occurs at every level of the sensory pathways innervating the colon, these changes provide an underlying mechanism for the presentation of chronic abdominal pain in the absence of pathology in patients with IBS.

Having demonstrated the underlying mechanistic processes by which chronic abdominal pain can occur, we determined whether it could be reversed. Here, we show that chronic daily treatment with linaclotide, an FDA-approved GC-C agonist for the treatment of IBS-C, (a) reversed mechanical hypersensitivity of colonic nociceptors, (b) reduced the number of activated dorsal horn neurons in response to CRD, (c) reduced the severity of colonic afferent central terminal sprouting, and, correspondingly, (d) normalized abdominal pain to CRD back to control levels (Figure 9L). These antinociceptive and analgesic effects are driven by activation of GC-C on colonic epithelial cells and the corresponding release of cGMP (4, 6, 8). We show that linaclotide itself does not inhibit the excitability of colonic nociceptors, whereas its downstream effector cGMP causes dose-dependent inhibition of action potential firing, particularly in CVH states. We also show conclusively for the first time to our knowledge that cGMP acts on a membrane target that is accessed from an extracellular site to inhibit nociceptors. The precise molecular target that cGMP acts on extracellularly remains elusive but is the subject of continued investigation. We also observed that human DRG neurons, with a pathological phenotype following culture in inflammatory mediators, have an increased responsiveness to cGMP. Taken together, these findings demonstrate how chronic daily linaclotide treatment reduces chronic colonic hypersensitivity and chronic abdominal pain in a preclinical model of IBS. This may explain why long-term clinical use of linaclotide results in more IBS-C patients reporting abdominal pain relief over time (4, 5), particularly if their underlying neuroplasticity is more entrenched following years of symptoms.

Recently, there has been an increased appreciation that IBS patients also suffer from a wide-range of extraintestinal comorbidities, including OAB and IC-PBS (13). Although these symptoms contribute to the poor quality of life experienced by IBS patients, the underlying etiology of these comorbidities has been unclear. Here, we show that colitis-induced chronic colonic afferent hypersensitivity subsequently results in chronic bladder afferent hypersensitivity to mechanical and chemical stimuli. This leads to chronic hyperexcitability of bladder-innervating DRG neurons and, ultimately, chronic dysfunction of bladder voiding (Figure 9K). These chronic changes in bladder function are not due to colitis-induced inflammation of the bladder, nor due to changes in the contractility of the bladder. We show that bladder dysfunction takes several weeks to develop and occurs following the resolution of colitis and following the development of colonic hypersensitivity, which commonly presents 3–7 days after induction of colitis (20, 30). Accordingly, these findings provide, for the first time to our knowledge, a mechanistic basis as to why IBS patients may also suffer from concurrent OAB/IC-PBS, particularly without a prior bladder infection or insult.

Our dual-retrograde tracing studies from the colon and bladder identified a small population of colon-innervating DRG neurons that also innervate the bladder (~15%), called dichotomizing afferents. As previously reported, these afferents have a single soma in the DRG but bifurcating axons that project to either the colon or bladder, respectively (14–16). Accordingly, dichotomizing afferents have been proposed as a mechanism for viscerovisceral crosstalk and the basis of cross-organ sensitization (15, 16, 31, 32). These dichotomizing afferents likely contribute directly to the cross-organ sensitization observed from the colon to the bladder in the current study, as they provide a clear mechanism by which sensitization of colonic afferents results in sensitization of bladder afferents. However, as they represent only approximately 15% of colon-innervating afferents, they are...
Figure 9. Colon- and bladder-innervating dorsal root ganglion neurons are largely distinct but their central terminals are closely apposed within the spinal cord. Retrograde tracer from colon- (CTB-555; magenta), bladder- (CTB-488; blue), or dual-traced (white) neurons in CLARITY cleared TL (L1) and LS (L6) dorsal root ganglia (DRG) from (A) control and (B) CVH mice. Scale bar: 100 μm. (C and D) Quantitative data of the number of colon-only, bladder-only, or dual-traced neurons per ganglia within (C) L1 and (D) L6 DRG (N = 3–5 mice per group). Data indicate no significant difference in the total number of colon-only, bladder-only (P = 0.058, unpaired t test), or dual-traced populations of neurons in control and CVH states. (E and F) Quantitative data of dual-traced neurons,
expressed as a percentage of colon-innervating neurons in (E) L1 and (F) L6 DRG. Data indicate no significant difference between control and CVH. (G and H) Spinal cord (50-μm sections) showing retrograde tracer from the colon (magenta) or bladder (blue). Imaging reveals that the central terminals of colon-innervating or bladder-innervating DRG neurons are in close apposition to one another within the dorsal horn, including within the lateral spinal nucleus and the lumbar dorsal column (repeated in N = 3 mice). Scale bar: 100 μm. (I and J) Enlarged images from insets within H. Scale bar: 30 μm. (K) Diagrams detailing changes in colon- and bladder-innervating sensory pathways during CVH and (L) how chronic linaclotide treatment normalizes colonic nociception and, subsequently, normalizes bladder afferent function and voiding. Data represent mean ± SEM. P values are based on unpaired t tests (E-F).

Overall, we have identified that both chronic abdominal pain and chronic bladder dysfunction occur in CVH states following the resolution of colitis. Our findings shed light on the mechanisms of cross-organ sensitization and provide the tantalizing prospect of treating multiple syndromes concurrently, while avoiding the debilitating side effects of current opioid-based pain treatments. Our findings may also have...
relevance beyond patients with IBS, as 30% of patients primarily defined as having OAB or IC-PBS exhibit symptoms of IBS among their most common comorbidities (11). Linaclotide is FDA approved, well tolerated by patients, with few side effects, and may therefore provide a safe alternative treatment for these patients. Consequently, our findings identify mechanisms that may be taken advantage of in the future for the treatment of comorbid pelvic pain symptoms.

Methods

For extensive and details descriptions of the methodology used, please see the Supplemental Methods.

Animals and ethics. Male C57BL/6J mice aged 13–17 weeks were used for adult studies. Some experiments also utilized male mice lacking GC-C (gucy2c−/−, in-house breeding colony at SAHMRI), which were generated as described previously (39). For FRET studies, R26-CAG-mcGi500 mice, which contain the sensor cGi500 under control of the ubiquitous CAG promoter, were used. R26-CAG-mcGi500 mice were generated as described previously (27).

Mouse model of CVH. Mice were administered intracolonic TNBS and developed colitis (4, 18–21), with significant increases in MPO activity (Supplemental Figure 1). While colonic inflammation spontaneously healed over a 7-day period (Supplemental Figure 1), these mice subsequently developed chronic colonic afferent hypersensitivity in the postinflammatory state (4, 18–21).

Study design. Mice were randomly assigned to either (a) control or (b) CVH cohorts and then randomly assigned to 1 of 3 groups: those that received (a) no gavage, or (b) once daily 100-μl oral gavage of linaclotide (3 μg/kg/d) for 14 days, or (c) vehicle (water) once daily 100-μl oral gavage for 14 days. Daily oral administration began from 14 days after TNBS administration (or time/day matched for control animals) until 28 days after TNBS administration.

In vivo VMR to CRD. We assessed in vivo visceral sensitivity to CRD (the distension pressures 20, 40, 60, and 80 mmHg were used for these studies, each 20-second duration, applied at 4-minute intervals) using abdominal electromyography in fully awake animals. Colonic compliance was assessed by applying graded volumes (40–200 μl, 20-second duration) (40–42).

Ex vivo single-fiber colonic nociceptor recordings. Ex vivo single-fiber colonic nociceptor recordings were made from control, CVH, or GC-C null (gucy2c−/−) mice using standard protocols (4, 18, 19, 21, 41).

Visualization of pERK-activated neurons within the dorsal horn of the spinal cord following noxious CRD. 80 mmHg CRD was performed (10 seconds on, 5 second deflation, repeated 5 times). After anesthetic overdose, mice were fixed by transcardial perfusion, the spinal cord removed and cryoprotected. Frozen sections were cut and incubated with monoclonal-rabbit anti-phosphorylated-MAP-kinase-ERK-1/2 (pERK) (Cell Signaling Technology, 4370) visualized with Alexa Fluor 488 (ThermoFisher Scientific, A-21441) (4, 23).

Retrograde tracing to label the cell bodies or central terminals of colon or bladder afferents. Cholera toxin subunit-B conjugated to Alexa Fluor 555 (CTB-555) was injected at 3 sites subserosally within the distal colon, while CTB-488 was injected into 3 sites into the bladder. Animals were left to recover for 4 days to identify cell bodies within the DRG or for 7 days to identify central terminals within the spinal cord (18, 23, 41).

Patch-clamp recordings of colon- or bladder-innervating DRG neurons. Whole-cell patch-clamp recordings in current clamp mode were made from retrogradely traced colon- or bladder- innervating DRG neurons. 10 pA–depolarizing pulses of 500-millisecond duration were applied to determine rheobase (current required to fire an action potential) (18, 21).

Human DRG neuron patch-clamp recordings. Human DRG neurons were acquired from organ donors with ethical consent, and whole-cell patch-clamp recordings were performed in current-clamp mode to determine rheobase (18).

FRET-based cGMP imaging in DRG neurons. DRG neurons were isolated from R26-CAG-mcGi500(L1) embryos that express a membrane-targeted version of the FRET-based cGMP sensor cGi500 under control of the ubiquitous CAG promoter. FRET/cGMP imaging was performed 24 hours after plating DRG neurons (27).

Bladder-voiding pattern analysis. Mice were individually housed in cages lined with filter paper for 3 hours. Filter paper was collected immediately prior to intracolonic TNBS administration and at days 7, 14, 21, and 28 after TNBS administration or the same time point for control mice. Filter paper was imaged using a Bio-Rad ultraviolet transilluminator and digitized into binary images using ImageJ (NIH).

Ex vivo electrophysiology for bladder afferent recordings and contractility studies. Whole pelvic nerve recordings were conducted in response to ramp distension (30 μl/min to 30 mmHg) (37, 43, 44). Studies
also determined the responsiveness of bladder afferents to intravesically applied linaclotide or \( \alpha\beta\text{Me-ATP} \), carbachol, or capsaicin.

**In situ hybridization mRNA detection of GC-C.** In situ hybridization mRNA detection of GC-C was performed in formalin-fixed, paraffin-embedded bladder and colon sections from GC-C\(^{+/+}\) and GC-C\(^{-/-}\) mice using the RNAscope 2.5 LS assay.

**Q-RT-PCR for GC-C in bladder and colonic epithelial cells.** The urothelial/epithelial layers were removed from bladder or colon, respectively, isolated and RNA extracted. Q-RT-PCR was performed with commercially available hydrolysis TaqMan probes (Thermo Fisher Scientific) for GC-C, TRPV4, and Hprt. Relative abundance was estimated using \( \Delta \text{Cq} \) method.

**Statistics.** Data are expressed as mean \( \pm \) SEM or the percentage of neurons/afferents. Figures were prepared in GraphPad Prism 7 Software; \( N \) equals the number of animals, while \( n \) equals the number of neurons/afferents. Differences were considered significant at a level of \( P < 0.05 \). Visceromotor responses (VMRs) to CRD data were statistically analyzed by generalized estimating equations followed by LSD post hoc test using SPSS 23.0 (IBM). All other data were analyzed using GraphPad Prism 7. These data were analyzed using (a) 1-way ANOVA. If data were normally distributed, they were analyzed using repeated-measures 1-way ANOVA, with post hoc analysis conducted by making all possible comparisons among the treatment groups with Tukey’s tests. If data were nonparametric, they were analyzed using Kruskal-Wallis 1-way ANOVA, and Dunn’s test was used to assess any post hoc differences in comparisons among all groups. (b) If data were normally distributed, they were analyzed by repeated-measures 2-way ANOVA with post hoc Bonferroni or Tukey’s tests and (c) paired or unpaired 2-tailed \( t \) tests or (d) \( \chi^2 \) analysis. The specific tests used to analyze each data set are indicated within the individual figure legends.

**Study approval.** The animal ethics committees of SAHMRI, Flinders University, the University of Adelaide, and the University of Tübingen approved experiments involving animals. All experiments conformed to the relevant regulatory standards and the ARRIVE guidelines. All human tissues used for the study were obtained by legal consent from organ donors in the US. AnaBios’s procurement network includes only US-based organ procurement organizations and hospitals. Policies for donor screening and consent are the ones established by the United Network for Organ Sharing. Organizations supplying human tissues to AnaBios follow the standards and procedures established by the US Centers for Disease Control and are inspected biannually by the Department of Health and Human Services. Tissue distribution is governed by internal IRB procedures and compliance with HIPAA regulations regarding patient privacy. All transfers of donor organs to AnaBios are fully traceable and periodically reviewed by US federal authorities.

**Author contributions**

AD, JC, JM, CBK, ISS, and SMB designed, performed, and analyzed the VMR to CRD studies. JC and SMB designed, performed, and analyzed the colonic afferent recordings. AMH and SMB designed, performed, and analyzed the pERK and retrograde tracing studies. SP, RF, CBK, and ISS designed, performed, and analyzed the FRET cGMP experiments. LG, GYR, and SMB designed, performed, and analyzed the patch-clamp experiments on mouse colon- and bladder-innervating DRG neurons. LG and SMB designed, performed, and analyzed the bladder afferent recordings and bladder-voiding patterns analysis. PM, AG, ISS, and SMB designed, performed, and analyzed the patch-clamp recordings on human DRG neurons. PG and GH designed, performed, and analyzed the in situ hybridization studies. SGC and SMB designed, performed, and analyzed the Q-RT-PCR and MPO experiments. AMH and SGC performed DRG CLARITY experiments. LG and SGC performed the histology experiments. All authors contributed to the discussion and interpretation of the results. SMB wrote the manuscript with contributions and suggestions from all authors.

**Acknowledgments**

We thank Tracey O’Donnell and Jessi Moore for their technical assistance. This work was supported by research grant funding from Ironwood Pharmaceuticals and Allergan (to SMB), DFG grant FOR 2060 (FE 438/5-2 and FE 438/6-2 to RF), the Fund for Science (to RF), a National Health and Medical Research Council of Australia (NHMRC) R.D. Wright Biomedical Research Fellowship (APP1126378 to SMB), NHMRC Australia project grants (1083480, 1139366, and 1140297 to SMB), an Australian Research Council (ARC) Discovery Early Career Research Award (DE130100223 to AMH), and an ARC Discovery Project grant (DP180101395 to AMH and SMB).
Address correspondence to: Stuart M. Brierley, Visceral Pain Research Group, Level 7, South Australian Health and Medical Research Institute (SAHMRI), North Terrace, Adelaide, SA 5000, Australia. Phone: 61.8.8128.4848; Email: stuart.brierley@flinders.edu.au.

CBK’s present address is: Synlogic, Cambridge, Massachusetts, USA.

ISS’s present address is: Decibel Therapeutics, Cambridge, Massachusetts, USA.


